T863

• CAT Number: I004632
• CAS Number: 701232-20-4
• Molecular Formula: C22H26N4O3
• Molecular Weight: 394.2
• Purity: ≥95%
• Target: DGAT
• Solubility: DMSO: 15 mg/mL
• Storage: 2-8°C
• IUPAC Name: 2-[4-[4-(4-amino-7,7-dimethylpyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]acetic acid
• InChI: InChI=1S/C22H26N4O3/c1-22(2)19(26-18-20(23)24-12-25-21(18)29-22)16-9-7-15(8-10-16)14-5-3-13(4-6-14)11-17(27)28/h7-10,12-14H,3-6,11H2,1-2H3,(H,27,28)(H2,23,24,25)
• InChIKey: FUIYMYNYUHVDPT-UHFFFAOYSA-N
• SMILES: CC1(C(=NC2=C(N=CN=C2O1)N)C3=CC=C(C=C3)C4CCC(CC4)CC(=O)O)C

T-863（Cat No.:I004632） is a orally active, selective, and potent inhibitor of DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1). It interacts with the acyl-CoA binding site of DGAT1, effectively inhibiting the synthesis of triacylglycerol in cells. By targeting DGAT1, T-863 demonstrates its ability to modulate lipid metabolism and potentially impact diseases associated with excessive triacylglycerol accumulation. Its specificity and potency make T-863 a promising candidate for further exploration in the development of therapeutic interventions targeting DGAT1 and related metabolic disorders.

Reference

[1]. Cao J, et al. Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem. 2011 Dec 2;286(48):41838-51.
[2]. Dow RL, et al. Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core. Bioorg Med Chem Lett. 2011 Oct 15;21(20):6122-5.
[3]. Qian Y, et al. Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes. J Med Chem. 2011 Apr 14;54(7):2433-46.